

Product Datasheet

AF9 Antibody - BSA Free NB100-1565

Unit Size: 100 ul

Store at 4C. Do not freeze.

www.novusbio.com



technical@novusbio.com

Publications: 2

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NB100-1565

Updated 9/9/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NB100-1565



NB100-1565

AF9 Antibody - BSA Free


Product Information	
Unit Size	100 ul
Concentration	1.0 mg/ml
Storage	Store at 4C. Do not freeze.
Clonality	Polyclonal
Preservative	0.09% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	Tris-Citrate/Phosphate (pH 7.0 - 8.0)

Product Description	
Description	Novus Biologicals Rabbit AF9 Antibody - BSA Free (NB100-1565) is a polyclonal antibody validated for use in IHC, WB and IP. Anti-AF9 Antibody: Cited in 2 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	4300
Gene Symbol	MLLT3
Species	Human
Immunogen	The immunogen recognized by this antibody maps to a region between residues 250 and 300 of human ALL1 Fused Gene from Chromosome 9 Protein using the numbering given in entry NP_004520.1 (GeneID 4300).


Product Application Details	
Applications	Western Blot, Immunohistochemistry-Paraffin, Immunohistochemistry, Immunoprecipitation
Recommended Dilutions	Western Blot 1:5000-1:15000, Immunohistochemistry 1:500 - 1:2000, Immunoprecipitation 1-4 ug/mg of lysate, Immunohistochemistry-Paraffin 1:500 - 1:2000
Application Notes	Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections.

Images


Western Blot: AF9 Antibody [NB100-1565] - Detection of Human AF9 on HeLa whole cell lysates using NB100-1565. AF9 was also immunoprecipitated using rabbit anti-AF9 antibodies NB100-1564, NB100-1566 and another AF9 Ab.




Immunohistochemistry-Paraffin: AF9 Antibody [NB100-1565] - Section of human ovarian carcinoma. Antibody: Affinity purified rabbit anti-AF9 used at a dilution of 1:1,000 (1ug/ml). Detection: DAB




Activity of compounds 1–3 on ENL and AF9 in MLL1-r leukemia cells. a–e Levels of ENL, AF9 and β -actin (as a control) in a–d MV4;11 and e Molm-13 cells upon treatment with compounds 1 (a/d/e), 2 (b), and 3 (c) at the specified concentrations for 24 h, showing they induced degradation of ENL with their dose-responsive curves for calculating DC50 shown at right. AF9 levels were not reduced; f time-dependent degradation of ENL in MV4;11 cells by 1 (500 nM); g–i ENL levels in MV4;11 cells upon pre-treatment for 2 h with SGC-iMLLT (Inh, g), thalidomide (Tha, h) and bortezomib (Bor, i) followed by co-treatment with 1 (500 nM) for 24 h, showing these three compounds can dose-dependently inhibit 1-mediated ENL degradation Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/35395864>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Activity of compounds 1–3 on ENL and AF9 in MLL1-r leukemia cells. a–e Levels of ENL, AF9 and β -actin (as a control) in a–d MV4;11 and e Molm-13 cells upon treatment with compounds 1 (a/d/e), 2 (b), and 3 (c) at the specified concentrations for 24 h, showing they induced degradation of ENL with their dose-responsive curves for calculating DC50 shown at right. AF9 levels were not reduced; f time-dependent degradation of ENL in MV4;11 cells by 1 (500 nM); g–i ENL levels in MV4;11 cells upon pre-treatment for 2 h with SGC-iMLLT (Inh, g), thalidomide (Tha, h) and bortezomib (Bor, i) followed by co-treatment with 1 (500 nM) for 24 h, showing these three compounds can dose-dependently inhibit 1-mediated ENL degradation Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/35395864>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Activity of compounds 1–3 on ENL and AF9 in MLL1-r leukemia cells. a–e Levels of ENL, AF9 and β -actin (as a control) in a–d MV4;11 and e Molm-13 cells upon treatment with compounds 1 (a/d/e), 2 (b), and 3 (c) at the specified concentrations for 24 h, showing they induced degradation of ENL with their dose-responsive curves for calculating DC50 shown at right. AF9 levels were not reduced; f time-dependent degradation of ENL in MV4;11 cells by 1 (500 nM); g–i ENL levels in MV4;11 cells upon pre-treatment for 2 h with SGC-iMLLT (Inh, g), thalidomide (Tha, h) and bortezomib (Bor, i) followed by co-treatment with 1 (500 nM) for 24 h, showing these three compounds can dose-dependently inhibit 1-mediated ENL degradation Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/35395864>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Activity of compounds 1–3 on ENL and AF9 in MLL1-r leukemia cells. a–e Levels of ENL, AF9 and β -actin (as a control) in a–d MV4;11 and e Molm-13 cells upon treatment with compounds 1 (a/d/e), 2 (b), and 3 (c) at the specified concentrations for 24 h, showing they induced degradation of ENL with their dose-responsive curves for calculating DC50 shown at right. AF9 levels were not reduced; f time-dependent degradation of ENL in MV4;11 cells by 1 (500 nM); g–i ENL levels in MV4;11 cells upon pre-treatment for 2 h with SGC-iMLLT (Inh, g), thalidomide (Tha, h) and bortezomib (Bor, i) followed by co-treatment with 1 (500 nM) for 24 h, showing these three compounds can dose-dependently inhibit 1-mediated ENL degradation Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/35395864>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Activity of compounds 1–3 on ENL and AF9 in MLL1-r leukemia cells. a–e Levels of ENL, AF9 and β -actin (as a control) in a–d MV4;11 and e Molm-13 cells upon treatment with compounds 1 (a/d/e), 2 (b), and 3 (c) at the specified concentrations for 24 h, showing they induced degradation of ENL with their dose-responsive curves for calculating DC50 shown at right. AF9 levels were not reduced; f time-dependent degradation of ENL in MV4;11 cells by 1 (500 nM); g–i ENL levels in MV4;11 cells upon pre-treatment for 2 h with SGC-iMLLT (Inh, g), thalidomide (Tha, h) and bortezomib (Bor, i) followed by co-treatment with 1 (500 nM) for 24 h, showing these three compounds can dose-dependently inhibit 1-mediated ENL degradation Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/35395864>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Li X, Yao Y, Wu F, Song Y A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth Journal of hematology & oncology 2022-04-08 [PMID: 35395864] (WB, Human)

Dittmar G, Hernandez D P et al. PRISMA: Protein Interaction Screen on Peptide Matrix Reveals Interaction Footprints and Modifications- Dependent Interactome of Intrinsically Disordered C/EBP beta. iScience 2019-03-29 [PMID: 30884312] (IP, Human)



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NB100-1565

NBL1-13137	AF9 Overexpression Lysate
NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB100-1565

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

